Clinical Trials Directory

Trials / Unknown

UnknownNCT03893643

Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15

Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age

Status
Unknown
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
15 Years
Healthy volunteers
Not accepted

Summary

.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis. The purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.

Conditions

Interventions

TypeNameDescription
OTHERno interventionno intervention in an observational study

Timeline

Start date
2019-01-01
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2019-03-28
Last updated
2019-03-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03893643. Inclusion in this directory is not an endorsement.